Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is set to be the first company reviewed by the Sci-Tech Innovation Board under the new listing standards, focusing on innovative technology in biopharmaceuticals, specifically using rice to produce recombinant human albumin, addressing supply bottlenecks in critical bioproducts [1][2]. Group 1: Market Opportunity - The market for human serum albumin in China reached 36.1 billion yuan in 2023, with projections to grow to 57 billion yuan by 2030, yet over 60% of the supply is reliant on imports [2]. - The company targets this market gap by utilizing rice as a "bioreactor" to produce high-purity recombinant human albumin, significantly enhancing domestic production capabilities [2][3]. Group 2: Technological Innovation - Heyuan Biotechnology has developed two key technology platforms: Oryz HiExp for high expression of OsrHSA and Oryz Pur for efficient purification, achieving a purity level of over 99.9999% [3]. - The innovative "rice blood-making" technology has gained recognition, with the founder's story highlighted as a model of innovation in the biopharmaceutical field [3]. Group 3: Product Pipeline and Clinical Trials - The core product, HY1001, is expected to complete its Phase III clinical trial for treating liver cirrhosis-related hypoalbuminemia by May 2024, showing efficacy comparable to plasma-derived albumin [4]. - If approved, HY1001 will be the world's first recombinant protein drug produced using rice cell expression systems, providing a sustainable solution to the reliance on imported human albumin [5]. Group 4: Future Prospects and Funding - The company plans to raise 240 million yuan to expand its production capacity from 10 tons to 130 tons annually and to support new drug development projects [8]. - Upon full implementation, Heyuan Biotechnology aims to establish a complete industrial chain from "medicinal rice cultivation to albumin extraction and drug manufacturing" [9].